Comparing Ibrance vs Orserdu
| Ibrance (palbociclib) | Orserdu (elacestrant) |
|
|---|
| Ibrance (palbociclib) | Orserdu (elacestrant) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Prescribed for Breast Cancer. Orserdu may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
|
|||||||||||||||
| More about Ibrance (palbociclib) | More about Orserdu (elacestrant) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Ibrance has an average rating of 6.8 out of 10 from a total of 85 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 29% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Ibrance side effects |
View all Orserdu side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Ibrance prices |
View all Orserdu prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
29 hours |
50 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 497 drugs are known to interact with Ibrance:
|
A total of 292 drugs are known to interact with Orserdu:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
February 03, 2015 |
January 27, 2023 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.